All News

CAR-T

Are we putting the CAR-T before the horse?

Richard Conway, MBBChBAO, PhD

CAR T-cells have been a revolutionary development in rheumatology. We have seen a population of patients with severe refractory autoimmune conditions almost overnight presented with the prospect of not just improvement, but of a cure.

Read Article
question marks

Psoriatic Arthritis: Which biologic agent is the best first choice?

Brian Jaros, MD

A growing arsenal of therapeutic targets in psoriatic arthritis (PsA) has enhanced the landscape of treatment in patients with this disease.

Read Article
Simulation modeling by Patel et al helps generate probability of remission, relapse, and adverse events in newly dx AAV Projected risk by model were similar to observed rates in RCTs @RheumNow #ACR25 Abst 1764 https://t.co/xevkJ2Ih0M

Links:

Brian Jaros, MD Dr_Brian_MD ( View Tweet)
#1724 MAIT cells central in RA pathogenesis. These innate-like T cells accumulate in synovial fluid, driving fibroblast activation, cytokine release & joint damage. Blocking MAIT activation or deleting MR1 reduces arthritis in mice- a potential new target in RA. @RheumNow #ACR25

Mrinalini Dey DrMiniDey ( View Tweet)

The Power of Gamma Delta T Cell for Autoimmunity https://t.co/wIMu5r7b3D More on T Cell engagers , this time with gama delta T cell ( tiny but mighty ). Kate Roslin talks about advantages of this protocol. (No cytokines thus less toxicity). @Yuz6Yusof @RheumNow #ACR25

Links:

Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)

#ACR25 Please find my video interview with Dr Kate Rochlin on a novel Bi-specific T-cell engager (BiTE) in development which binds to pan-gamma delta T-cell instead of CD3 to minimise risk of cytokine release syndrome side effect. Abstr#1535 @RheumNow https://t.co/MOmUm41cyA https://t.co/TgIUGgWGw5

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#ACR25 Please find my video and take on Abstr#0646. Promising new Bi-specific T-cell engager (BiTE) other than Blinatumomab in #SLE @RheumNow https://t.co/5JrLG41nsD https://t.co/KeY6AkHUNK

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Progressive BiTE in SLE 2 https://t.co/ykMQmSAdlb More on BiTES in SLE by the one and only @Yuz6Yusof Bi specific Tcell engager ( CD3-CD19). @RheumNow #ACR25

Links:

Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)

New Paradigms in RA Treatment https://t.co/CqpI2znglE @jeffsparks Highlights new trials in RA 1-Neuro immune modulation ( Vagal nerve stimulation). 2-Targeting pathogenic T cells 3-T reg CAR-T ( Peace maker). @RheumNow #ACR25

Links:

Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)

IL-5 agents may in fact work for severe EGPA manifestations Although severe pt were excluded from enrollment in MANDARA, post-hoc and OLE data suggest development of severe manifestations is rare in benra treated patients @RheumNow #ACR25 https://t.co/slUpAT9mWo

Links:

Brian Jaros, MD Dr_Brian_MD ( View Tweet)

Abstract 1657: Can LLMs track medication history? GPT-4 outperformed most LLMs in identifying TNFi start/stop events and reasons for switch. 💊 Common reasons for TNFi switching: lack of effectiveness, adverse events, and insurance/cost barriers. @RheumNow #ACR25 https://t.co/5FUR9tBoyu

Links:

Akhil Sood MD, MS AkhilSoodMD ( View Tweet)

#ACR25 Abstr#1532 “The more the merrier” or “Too many cooks..” Preliminary data of CTA313, dual CD19-BCMA CAR-T in 15 #SLE pts showed deep depletion & good response. Global study is planned. Will have to keep on eye on safety (G3 herpes zoster, pneumonia & neutropenia) @RheumNow https://t.co/0KQa9K6bYB

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
New tx for IPF/autoimmune ILD, nerandomilast (PDE4Bi) Subgroup analysis from FIBRONEER-ILD, marginally less FVC worsening (-65mL tx grp vs -107mL plbo grp) & no clear improvements in dyspnea/fatigue/cough But also... 6% absolute reduction in overall, persisted (small n) in https://t.co/Faf26UZuDx

Links:

Mike Putman EBRheum ( View Tweet)
Beyond biologics: RA meets bioelectric medicine. In RESET-RA, TNFi inadequate response or intolerant (n=124), vagus nerve stimulation led to significant & durable improvement 🔹 ACR20 3mo: 42% active vs 18% sham (p=0.0057) 🔹 Benefits through 12mo @RheumNow #ACR25 A#1675

Jiha Lee JihaRheum ( View Tweet)

This study evaluated effectiveness of SEC in PsA prevention of a subgroup of pts from SELENA: PsO pts w/o PsA & nail dse (n=292) At 5 yrs: 🎯98.3% didn't develop PsA (yEAIR 0.49) 🎯 Sustained PASI, PGA 0/1 💡Longterm SEC effective for PsA prevention? #ACR25 @RheumNow Abs1463 https://t.co/t7P1Oerbrw

Links:

sheila RHEUMarampa ( View Tweet)
Sun et al. Telitacicept in SARD-ILD (pSS, ASS, RA). 25 patients. Improvements in CT, PFTs, 6MWT. @RheumNow #ACR25 Abstr#1361 https://t.co/q679LOaOyL

Links:

Richard Conway RichardPAConway ( View Tweet)
In ICONIC-LEAD, adolescents (12 to <18 years) with moderate-to-severe psoriasis treated with icotrokinra (ICO) achieved Investigator Global Assessment (IGA) 0/1 in 84.1% vs 27.3% (placebo) and PASI 90 in 70.5% vs 13.6% at Week 16. Week 24 responses reached 88.6%. Safety profile https://t.co/L7h8BlnWaO

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Case series of 5 patients with binutuzumab (CD20) in AAV Short story short; it worked. Of course it worked. Obviously it worked. Everyone knew it would work. Why aren't we doing more TRIALS with new/better B cell inhibitors in AAV? #ACR25 @RheumNow Abstr#1601 https://t.co/H6Zz3Tf3xo

Links:

Mike Putman EBRheum ( View Tweet)
A combined biomarker assay may predict which AAV patients will not respond to RTX therapy A next step towards precision / personalized rheumatology? @RheumNow #ACR25 Abst 1602 https://t.co/gcrZUNV0b9

Links:

Brian Jaros, MD Dr_Brian_MD ( View Tweet)
Icotrokinra, the new kid on the bloc! Targeted oral peptide IL-23R-inhibitor Effective in Ph2 and Ph3 in PSO Adults Data in Adolescents (12-18yo) with PSO ICO 200mg QD 44pts vs. PBO 22pts 16wks All pts received ICO wk16-wk24 Clear/Almost clear skin IGA 0/1 84% vs. 24% PASI 90 https://t.co/77YvXtdLi1

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×